Comparative Pharmacology
Head-to-head clinical analysis: LETAIRIS versus OPSYNVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LETAIRIS versus OPSYNVI.
LETAIRIS vs OPSYNVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ambrisentan is an endothelin receptor antagonist that selectively inhibits endothelin-1 (ET-1) binding to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle cells, reducing vasoconstriction and smooth muscle proliferation.
OPSYNVI is a dual endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE5) inhibitor. Macitentan blocks endothelin-1 (ET-1) receptors (ETA and ETB), reducing vasoconstriction and proliferation. Tadalafil inhibits PDE5, increasing cGMP levels and causing vasodilation.
5 mg orally once daily, with or without food; may increase to 10 mg once daily if tolerated.
10 mg orally once daily, in combination with tadalafil 20 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 6–12 hours) in healthy adults.
Terminal elimination half-life approximately 15 hours (range 10–20 hours) in patients with pulmonary arterial hypertension; supports twice-daily dosing.
Primarily via biliary/fecal elimination (approximately 80% of metabolites and unchanged drug; ~20% renal as metabolites).
Primarily fecal (approximately 66% of absorbed dose) and renal (approximately 22% as unchanged drug and metabolites). Biliary excretion is negligible.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist/Phosphodiesterase-5 Inhibitor Combination (PAH)